ABSTRACT
INTRODUCTION: Our current understanding of the pathophysiology of chronic venous disease (CVD) suggests that veno-active drugs (VAD) can provide effective symptom relief. Few studies have conducted head-to-head comparisons of VAD and placebo while also assessing objective measures (such as water plethysmography findings and tibiotarsal joint range of motion) and patient-reported quality of life outcomes. OBJECTIVES: To compare the effects of different VAD on limb volume reduction, tibiotarsal range of motion, and quality of life. METHODS: 136 patients with CVD (CEAP grades 2-5) were randomly allocated into four groups to receive micronized diosmin + hesperidin, aminaphthone, coumarin + troxerutin, or placebo (starch). Patients were administered a questionnaire consisting of a quality of life (QoL) measure designed specifically for persons with CVD, and underwent tibiotarsal joint angle measurement and water plethysmography of the lower extremity before and 30 days after pharmacological intervention. Assessors were blind to the treatment groups. RESULTS: Nine patients dropped out of the trial. Data collected from the 127 remaining patients was considered for statistical analysis. There were no differences in tibiotarsal joint range of motion. Volume reductions ≥100 mL were more frequent in the diosmin + hesperidin group than in any other group. QoL scores were best in the aminaphthone group, and between-group differences were found on individual analysis of questionnaire items. CONCLUSIONS: Use of VAD was associated with significant improvements in QoL as compared with placebo. VAD may be effective for providing symptom relief in patients with CVD.
Subject(s)
Cardiovascular Agents/therapeutic use , Venous Insufficiency/drug therapy , Biomechanical Phenomena , Brazil , Cardiovascular Agents/adverse effects , Chronic Disease , Coumarins/therapeutic use , Diosmin/therapeutic use , Double-Blind Method , Drug Therapy, Combination , Edema/diagnosis , Edema/physiopathology , Female , Foot Joints/drug effects , Foot Joints/physiopathology , Hesperidin/therapeutic use , Humans , Hydroxyethylrutoside/analogs & derivatives , Hydroxyethylrutoside/therapeutic use , Male , Plethysmography , Quality of Life , Range of Motion, Articular , Recovery of Function , Surveys and Questionnaires , Time Factors , Treatment Outcome , Venous Insufficiency/diagnosis , Venous Insufficiency/physiopathology , para-Aminobenzoates/therapeutic useABSTRACT
Diversas são as complicações possíveis da radioterapia na adjuvância do tratamento de neoplasias. Lesões actínicas de artéria subclávia em pacientes submetidos a este tipo de tratamento para neoplasia de mama são complicações conhecidas, porém com poucos relatos de casos publicados. No presente relato, descrevemos um caso de oclusão de artéria subclávia direita em paciente submetida à radioterapia para tratamento de neoplasia de mama, tratada com a revascularização convencional, com interposição de enxerto de politetrafluoretileno (PTFE). Na revisão da literatura realizada, foram encontrados doze casos descritos que evidenciaram diferentes opções terapêuticas. Concluímos que a arterite actínica de artéria subclávia é uma doença incomum, entretanto sua hipótese deve ser aventada em todos os pacientes com isquemia de membro superior já submetidos a tratamento de radioterapia.
Several complications may occur as a consequence of adjuvant radiotherapy for cancer. One of these complications is actinic lesions of the subclavian artery in patients undergoing radiotherapy for breast cancer; however, there are few reported cases. In the present case report, we describe a case of right subclavian artery occlusion in a patient undergoing radiotherapy for breast cancer. Occlusion was treated by means of conventional artery bypass with interposition graft with polytetrafluoroethylene (PTFE). Our extensive review of the literature revealed 12 reported cases showing the different treatment options performed. We concluded that actinic arteritis of the subclavian artery is an uncommon condition; however, its presence should be considered in all patients with upper limb ischemia who underwent radiotherapy.
